Share
Back to top
Oncology
-
When Craig was diagnosed with multiple myeloma, his wife Cara took on a new role: caregiver. Here, she shares the challenges—as well as the triumphs—of this difficult journey.
-
Rates of this blood cancer have jumped more than 125% worldwide since the 1990s. But there's reason to have hope: Today, life expectancy has at least doubled in some cases. That's thanks to increased research, new learnings and innovative advances—and Johnson & Johnson is at the forefront of this crucial work.
-
The Johnson & Johnson WiSTEM2D Scholars Award Program winners have big ideas—and an even bigger drive to inspire other women studying science, technology, engineering, math, manufacturing and design to pursue their dreams, too.
-
For National Cancer Prevention Month, we’re spotlighting three leading Johnson & Johnson female hematologists—innovators who are not only saving lives and advancing new treatments but also paving the way for the next generation of women in their field.
-
Algorithms, artificial intelligence, machine learning and other technologies are transforming the way physicians identify, treat and manage diseases. Here’s how Johnson & Johnson is putting the latest tools to work.
-
That's exactly what researchers at Johnson & Johnson are trying to find out. By partnering on a new study that's looking at the role gut microbes may play in the disease—and focusing on the underrepresented groups most affected—they hope to advance early-detection strategies and potential treatments.
-
Hidden in large amounts of digital information—such as anonymized medical records—may be the keys to transforming the future of healthcare. Troy C. Sarich, Ph.D., Johnson & Johnson's Chief Commercial Data Science Officer, shares how the company is carefully collecting, analyzing and harnessing this information to improve the health of people everywhere.
-
Artificial intelligence-enabled mobile screening units. Nasal swab genomic tests. Diagnostics that pair the right treatment with the right patient. For National Cancer Prevention Month, Johnson & Johnson researchers share the progress that's being made to thwart the #1 cancer killer.
-
Certain gene mutations can dramatically increase the risk of developing aggressive prostate cancer. That's why Johnson & Johnson is researching a new way to fight the disease—one that involves blocking cancer cells from repairing their own damaged DNA.
-
Most people know about side effects, like hair loss, that can accompany cancer treatment. But chemotherapy can also impact your skin. Oncodermatologists and Johnson & Johnson scientists looked into how to care for such skin—leading to a new science-backed line of cleansers, moisturizers and balms designed with cancer patients in mind.
-
In addition to its own cadre of scientists hard at work fighting the pandemic, Johnson & Johnson also supports external researchers and entrepreneurs equally dedicated to finding solutions for the current health crisis. We take a look at some of this groundbreaking work happening across the globe—from San Francisco to Seoul.
-
When you're the CFO of a company, you have a holistic view of how a pandemic can touch every aspect of a business, especially when it's a healthcare company. So we posed inquiring mind questions to Joe Wolk about what the past eight months have been like for him at the financial helm of the company—via a Zoom interview.
-
Cancer. Diabetes. Autoimmune diseases. They're the common illnesses we have a better chance at fighting, thanks to Dr. Cantley's pioneering work. Learn more about his "magic molecule" research.
-
Siddhartha Mukherjee, M.D., made his name as an oncologist, researcher and Pulitzer Prize-winning writer. Now he's the scientific adviser of an immuno-oncology start-up that's tackling a rare form of leukemia. In an exclusive interview, he reveals his vision for the future of cancer treatments.
-
For National Cancer Prevention Month, we retrace the 22-year journey it took to bring a potentially life-changing treatment for an aggressive form of bladder cancer to patients who may benefit most.
